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Objectives: Sleep disturbance is associated with persistence and exacerbation of 
chronic pain. As this relationship seems to be bidirectional, factors underpinning sleep 
disturbance may prove valuable in multimodal rehabilitation approaches. The aim of this 
cross-sectional study was to examine the impact of psychological symptoms on subjective and 
objective sleep measures in patients with chronic musculoskeletal pain (CMP) as compared to 
healthy controls (HC). 
Methods: Sleep was assessed by self-report questionnaires, actigraphy and 
polysomnography recordings in 56 patients (75.0% female; Mage = 41.7 years, SD = 10.8 
years) with CMP and compared to 53 matched HC (71.7% female; Mage = 41.8 years, SD = 
10.7). Mental distress (HSCL) and pain catastrophizing (PCS) were tested as predictors of 
objective and subjective sleep measures in multiple regression models, and their indirect 
effects were tested in bootstrapped mediation models. 
Results: The sleep data revealed substantially more subjective sleep disturbance 
(Hedge’s g: 1.32-1.47, p < .001), moderately worse sleep efficiency in the actigraphy 
measures (Hedges g: 0.5-0.6, p < .01) and less polysomnography measured slow wave sleep 
(SWS) (Hedges g: 0.43, p < .05) in patients as compared to controls. HSCL was strongly 
associated with the self-reported measures Insomnia Severity Index (ISI) and Pittsburgh Sleep 
Quality Index (PSQI). HSCL also partially explained the pain (CMP / HC) to sleep 
association, but HSCL was not associated with any of the objective sleep measures. More 
pain catastrophizing was related to less SWS.  
Discussion: The differences in subjective and objective sleep measures indicate that 
they probe different aspects of sleep functioning in patients with musculoskeletal pain, and 
their combined application may be valuable in clinical practice. Self-reported sleep 
disturbance seems to overlap with affective dimensions reflected by the HSCL- questionnaire.  
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Insomnia afflicts about 2 of 3 patients with chronic pain, and this association seems to 
be bidirectional.1,2 Those suffering from chronic musculoskeletal pain tend to have sleep 
characteristics comparable to insomnia, with both self-reported and objectively measured 
impairments.3-5 Comorbid sleep disturbance most likely contribute to the persistence and 
exacerbation of chronic pain,6 whereas non-disturbed sleep may alleviate pain.7 According to 
a meta-analysis by Tang, the expected palliation of pain following sleep interventions seems 
to be modest,8 still it may be of clinical interest to gain knowledge about factors contributing 
to sleep impairment in chronic pain conditions.  
Self-reported and objective sleep measures seem to be differentially related to pain.9-12 
Self-report measures generally yield larger group differences than actigraphy and PSG 
measures in case-controlled chronic pain studies, and may be more strongly associated with 
reported levels of pain in experimental studies.9,13 Polysomnography (PSG) is considered the 
gold standard of objective sleep recording, enabling assessment of both sleep continuity and 
sleep architecture, as well as detection of abnormal sleep related respiration and movement. 
However, the equipment may be perceived as intrusive, and is not suitable for long term 
monitoring. An actigraph, a wristwatch-like device measuring movement, is more convenient 
for longer recordings, and is regarded as valid proxy measure of sleep continuity in pain 
patients.14  
Meta-analyses of controlled PSG studies in pain conditions suggest impaired sleep 
continuity with reduced sleep duration (total sleep time, TST), increased wake time during the 
night (wake after sleep onset, WASO) and reduced sleep time/ time-in-bed ratio (sleep 
efficiency, SE), whereas increased interval from bed-time to sleep onset (sleep onset latency, 
SOL) does not seem to be as consistently reported.13,15 Among controlled actigraphy studies, 
several do not observe group differences in sleep continuity measures.9,16,17 Others report 
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group differences, most consistently for WASO and SE.18-20 In addition to differentiating 
groups, SE and WASO have been associated with reported pain,18,21 and SE was related to 
pain inhibition in an experimental study among pain patients.22 
Changes in sleep architecture, including amounts of slow wave sleep (SWS), are not 
uniform in studies of pain patients.3,13,15 Yet, reduced SWS was observed among men who 
reported higher pain intensity in a large population study, and may thus be of particular 
interest.23 In healthy persons, reduced SWS typically impairs subjective sleep quality, and 
increases the propensity to sleep at daytime.24 However, how psychological factors like 
mental distress and pain catastrophizing associate with the possible loss of SWS in pain 
patients is less well studied.  
Negative affect and mental distress is generally common in chronic pain,25 and several 
pain comorbidity studies examining self-reported sleep measures in chronic pain conditions, 
have pointed to depressive symptoms, pre-sleep worry and arousal as consistent risk factors of 
impaired sleep quality and insomnia.1,11,12,26-30 Cognitive responses to pain, as assessed by the 
Pain Catastrophizing Scale (PCS), may additionally contribute to arousal and reduced sleep 
quality.31 On the other hand, the associations between psychological symptoms and PSG or 
actigraphy indices of sleep continuity are less uniformly described, as several studies report 
significant associations, whereas others do not.12,18,19 
Mediation studies, recently reviewed by Whibley, suggest that affective and cognitive 
factors are involved as mediators in the reciprocal sleep-pain relationship.32 However, these 
studies lack objective sleep measures.32 In order to clarify the role of psychological symptoms 
for the pain-sleep association, it would accordingly be useful to study sleep both with 
subjective and objective measures. Such data would also be useful in statistical/mediation 
model building, aiming to clarify if a common underlying pathophysiology could explain 
these relationships.33 It would be of particular interest to study how both objective and 
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subjective sleep measures can be explained by psychological variables among healthy 
subjects and patients with chronic pain. 
The aim of this study was to estimate the influence of potentially modifiable 
psychological factors on sleep quality and insomnia-symptoms as well as PSG and actigraphy 
measured sleep disturbance, in patients with chronic musculoskeletal pain, as compared to 
healthy controls. The specific objectives were 1) to estimate polysomnographic and 
actigraphic sleep in pain patients compared to healthy controls using a blinded design, 2) to 
examine how mental distress and pain catastrophizing are associated with self-reported, 
actigraphy and PSG measures of sleep in pain patients and healthy controls and 3) to examine 
to what extent an association between pain (group affiliation) and sleep outcomes was 
explained by mental distress or pain catastrophizing as mediating variables.  
2 Materials and Method 
2.1 Participants and Procedure 
Patients attending the outpatient clinics at the Rehabilitation Department and the Pain 
Clinic, both at the University Hospital of North Norway (UNN), were invited by mail. Criteria 
for inclusion were visits at the respective clinics during the last 18 months, age 18-65 years 
and having chronic musculoskeletal pain, defined by selected ICD-10 codes (Table 1). 
Patients were excluded if they had a major medical condition (cancer, inflammatory, 
symptomatic heart or lung, metabolic or endocrine disease), neurologic condition, psychiatric 
illness, drug abuse, were pregnant or participated in ongoing intervention studies. Patients 
previously diagnosed with sleep disorder, other than insomnia, were excluded. A group of 
pain free controls, matched one to one by age (+/- 5 years), sex and season of investigation, 
were recruited by poster advertisements among hospital and university employees and blood 
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donors. The same exclusion criteria were assessed based on medical records and interview for 
both patients and controls. 
The study is a cross-sectional case-controlled observation study. Due to the purpose of 
another study, investigating seasonal variations in symptoms (paper submitted, in review), 
participants were enrolled either during summer or winter season. The study entailed one 
week of continuous actigraphy with accompanying sleep diary, and one night (first) of 
unattended polysomnography (PSG). The first appointment took place at the Department of 
Clinical Neurophysiology, UNN, where participants received detailed written and oral 
information, completed questionnaires, and had the devices for actigraphy and unattended 
home PSG attached. They returned the next morning to have the PSG unit disconnected, and 
finally returned after 7 days with the actigraphy device and completed sleep diary. 
Participants were instructed to conduct their daily life as usual during the study period. There 
were no restrictions to sleep schedule, habitual medication or daily activities, but periods of 
night shifts were avoided for participants with shift work.  
2.2 Self-report Measures 
Age, gender, educational level (high school vs higher education), marital status (single 
vs married/cohabiting), employment (no, yes), receiving social benefit (no, yes) and self-rated 
economic situation (poor/medium vs good) were registered. Medication was registered based 
on participants own reports at first visit. Regular medications were categorized into opioids, 
hypnotics, antidepressants, antiepileptic (taken as analgesic), NSAID/ paracetamol and 
“other”. The category “other” included sporadic use of the aforementioned drugs as well as 
other medications (antihistamine, antiasthmatic, thyroxine etc.).  
Pain severity items of a validated Norwegian version of the Brief Pain Inventory (BPI) 
short form were applied.34,35 Participants estimated their worst, least and average pain during 
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the last week, as well as their current pain. Each of the four items were rated on an 11-point 
numeric rating scale (from 0, no pain, to 10, worst imaginable pain). We used the mean 
severity score of these four items in the analyses of pain severity.  
The 25 item version of the Hopkins Symptoms Checklist (HSCL 25) is a self-report 
inventory assessing symptoms of depression and anxiety indicative of mental distress.36 Items 
are rated from 1-not at all to 4-very much, from which a global average score is calculated 
(range: 1-4). 
The validated Norwegian version of the Pain Catastrophizing Scale (PCS) was 
applied.37,38 Thirteen items covering rumination, magnification and helplessness, are rated on 
a five-point Likert scale (0=not at all, 1=to a slight degree, 2=to a moderate degree, 3=to a 
great degree, 4=all the time). The sum score (range 0-52) was used for analyses. 
The Insomnia Severity Index (ISI) encompasses seven items rated on a five-point 
Likert scale (0–4, total range 0-28).39 An ISI cut-off >14 indicates clinical insomnia,40 and the 
ISI is a recommended research measure of insomnia symptoms.41  
The Pittsburgh Sleep Quality Index (PSQI) comprises 19 items probing sleep quality 
and disturbance during the previous month, across seven components: 1) Subjective sleep 
quality, 2) sleep latency 3) sleep duration 4) habitual sleep efficiency 5) sleep disturbance, 6) 
sleep medication and 7) daytime dysfunction. Each component is scored 0 (no difficulty) to 3 
(severe difficulty), yielding a global score with a range of 0-21. A cut off score > 5 is 
recommended to distinguish good from poor sleepers.42 The PSQI is a recommended research 
measure of global sleep symptoms.41 The Norwegian translation has shown acceptable 
reliability and validity.43  
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2.3 Sleep Recording 
The Actiwatch Spectrum Plus device (Phillips Respironics, Inc., Murrysville, PA) was 
applied as a proxy-measure of sleep.  Good agreement with PSG for TST, SE and WASO has 
been reported in low back pain, whereas validity for SOL was poor.14 Stability of sleep 
variables over time (year) seem reasonable for TST, SE and SOL, but larger night-to-night 
variability (particularly SOL) requires 5-6 days of recording for reliable measures.44 The 
Actiwatch was applied on the non-dominant wrist, and was only to be removed shortly during 
shower or if required at work (e.g. due to hygiene or safety considerations). The participants 
registered their first sleep attempt and final morning awakening by pushing the event button 
as well as completing a sleep diary, reporting the hour of going to bed, attempting to sleep, 
waking up and getting out of bed as well as estimating sleep latency, and nightly awakenings. 
Actiware version 6.0.9 software was used for post-processing (30 second epochs, medium 
sensitivity for activity detection and an immobility threshold of 10 minutes for sleep onset). If 
necessary, information based on the event marker, sleep diary and light intensity information 
were consulted, in line with a published guideline.45 Rest periods were scored by a trained 
research assistant (psychology student) supervised by a specialist in clinical neurophysiology 
(first author). Both were blinded to participant identity and group affiliation. The variables 
associated with insomnia; total sleep time (TST), sleep onset latency (SOL), wake after sleep 
onset (WASO) and sleep efficiency (SE) were averaged across the recorded 7 days.  
SOMNOscreen equipment and Domino version 2.7.0 software (Somnomedics, 
Randersacker, Germany) were applied for PSG, and the recording and scoring were 
performed in accordance with The American Academy of Sleep Medicine (AASM) Manual 
for the Scoring of Sleep and Associated Events, version 2.4.46 The scoring was performed by 
the first author who was blinded to participant identity and group affiliation. Six EEG leads 
(F3/F4, C3/C4, O1/O2), right and left EOG and submental EMG were used for sleep scoring. 
Sleep disturbance in chronic musculoskeletal pain 
10 
 
Pressure flow nasal cannula, inductive thoracic and abdominal belts (effort) and oximetry 
were used for respiratory assessment. The AASM hypopnea scoring rule 1A was applied (≥ 
10 seconds duration of ≥ 30% of air flow reduction associated with a ≥ 3% decrease in 
oxygen saturation and/ or an EEG arousal). Bilateral pretibial EMG recordings were used for 
assessment of periodic limb movements (PLM). The participants used a marker button to 
indicate their first attempt to sleep. The variables TST, SOL, WASO, SE, distribution of sleep 
stages as proportion of TST (N1, N2, N3 (also termed slow wave sleep, SWS, in this paper) 
and REM), indexes of sleep stage shifts, wake bouts, arousals, limb movements (LM) in 
periodic LM sequences (PLM) and apneas/ hypopneas (AH) were obtained for the recording 
night. All indexes are denoted as number of events per hour of sleep (apnea hypopnea index, 
AHI, and periodic limb movement index, PLMI). 
2.4 Statistical Analyses 
The IBM SPSS 25 was used for general analyses, including the SPSS plugin 
PROCESS version 3 macro by Hayes for mediation analyses.47 
Due to highly skewed distributions, bootstrapped 95% confidence intervals based on 
5000 re-samplings were constructed for all analyses to derive empirically unbiased estimates 
of the sampling error.  
Crude group differences were assessed by independent Student’s t-tests and chi-square 
tests for continuous and dichotomous variables, respectively. In case of unequal variances 
(i.e., significant Levene’s test), the degrees of freedom were appropriately adjusted. Between-
group effect sizes are reported as Hedge’s g.  
Bivariate correlations, with estimation of Pearson correlation coefficients were 
assessed between the most important variables, separately in the CMP and HC groups.  
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Four multiple linear regression models with ISI, PSQI, SE (actigraphy) and SWS as 
dependent variables were assessed in each of the CMP and HC sub-groups. The 7-day 
actigraphy derived SE was preferred to the corresponding 1-day PSG measure as it was 
presumed superior as a measure of habitual sleep. The independent variables of interest, 
HSCL and PCS were entered in the regression model together with the covariates gender, age, 
education and AHI. The models were bootstrapped to provide unbiased confidence intervals. 
Standardized residuals were inspected for normality and heteroscedasticity.  
The regression analyses were replicated (without AHI as a covariate) after having 
participants with AHI>15 removed from the sample, as a sensitivity test examining the 
robustness of the results. 
Four mediation models were specified to investigate whether group differences (CMP 
vs HC) in the sleep measures ISI, PSQI, SE (actigraphy) and SWS could be explained by 
indirect effects through mental distress and pain catastrophizing. In situations considering 
multiple mediators, fitting a multiple mediation model may be preferable to several simple 
mediation models, as a) including multiple mediators enable estimation of the effect of a 
mediator conditional on the presence of other mediators, b) including multiple mediators in a 
single model allows the simultaneous estimation of their specific magnitudes, c) sequential 
simple mediation testing may suffer from an omission variable bias.48 Including correlated 
mediators are acceptable, however with possible drawbacks related to reduced statistical 
power due to increased parameter variance that yield wider confidence intervals.47,48 Mental 
distress and pain catastrophizing were thus entered simultaneously as mediators, but either 
were removed if non-significant (p>0.05). Standard errors and confidence intervals were 
bootstrapped.  
The mediation Model 4 (applied for simple and multiple mediation) of the PROCESS 
macro partitions the total effect (Y=icept+cX) in two underlying components: the indirect or 
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mediating effect (M=icept+aX) and the adjusted direct effect (Y’=icept+c’X+bM). Here, the 
indirect effect runs from group (X) through mental distress / pain catastrophizing (M: path a) 
to sleep as outcome (Y: path b), and is thus estimated as the product of a and b. If the indirect 
path (a*b) explains all variability in the outcome measure, the adjusted direct effect (c’) will 
turn non-significant. The size of the mediation effect is represented by the ratio between the 
indirect (a*b) to the direct or total effect (c). 
2.5 Ethical Approval 
The study was approved by the Regional Committee for Medical and Health Research 
Ethics, Office North (reference number 2015/2473). Written informed consent was obtained 
from all participants. 
3 Results:  
3.1 Sample Characteristics 
A total of 401 patients were invited to participate, of whom 91 responded. Based on 
criteria, 28 patients were excluded and 7 patients either moved or withdrew. The final sample 
consisted of 56 patients and 53 controls. The distribution of ICD-10 diagnoses is given in 
Table 1. Three participants in the pain group were not available for PSG recording and the 
PSGs of two control participants were technically unsuccessful. There were artifacts in 
respiratory leads in four participants (one control, three pain patients) as well as in the leg-
movement leads in six participants (four controls, two pain patients), and they were excluded 
from analyses using these variables.  
3.2 Group Differences 
The numbers being unemployed, receiving social benefits and having poor economy 
were larger for patients compared to controls. Of the six patients using opioid medication, five 
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used tramadol (up to 200 mg daily dose) and one used a combination of paracetamol and 
codeine. Three patients used hypnotics (benzodiazepine-like drug), and five patients used the 
antidepressant amitriptyline in dosages intended for analgesia and sleep. One patient used 
escitalopram. Three patients used antiepileptic drugs for pain (Table 2). Due to small number 
of participants using diverse drugs with varying potential for affecting sleep, medication was 
not found useful as a covariate in further analyses. 
 As expected, patients reported significantly more pain symptoms (BPI), pain 
catastrophizing (PCS) and mental distress (HSCL) than control cases (Table 3). Patients also 
reported significantly more insomnia (ISI) and reduced sleep quality (PSQI) compared to 
controls (Table 4), and with strong effect sizes. Based on the ISI cut off score (> 14), the 
prevalence of insomnia was 30.4% and 3.8% (p < .001) in the patient and control groups, 
respectively. A corresponding analysis of the PSQI (cut off > 5) indicated that 76.8% and 
26.4% of the patients and controls, respectively, had impaired sleep quality (p < .001).  
The actigraphy data showed significant group differences of medium effect sizes 
including increased SOL and WASO, and reduced SE among CMP compared to HC. No 
significant group difference was observed for TST (Table 4). PSG showed no significant 
group differences in the sleep continuity variables, but the sleep stage distribution in patients 
showed less SWS (N3) and more light sleep (N2) compared to controls. There were no 
significant group differences in arousal index, sleep stage shift index, AHI or PLMI. (Table 
4). The number of participants displaying AHI above 15 was 14 (28.6%) and 9 (18%) among 
CMP and HC respectively, and for AHI above 30 the corresponding numbers were 4 (8.2%) 
and 1 (2%).  
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3.3 Correlation and Regression Analyses 
The bivariate correlations are available in Supplement Table 1. The regression 
analyses are presented separately for CMP and HC in Table 5. Mental distress, but not pain 
catastrophizing, was a significant predictor for both self-reported sleep outcomes, ISI and 
PSQI, among CMP and HC alike. Increased mental distress was associated with increased 
symptoms of insomnia and reduced sleep quality. Neither HSCL nor PCS significantly 
predicted SE (actigraphy), whereas PCS was significantly associated with SWS among 
patients with chronic pain solely. 
A sensitivity test was performed by repeating the regression analyses while excluding 
participants with AHI> 15. Although PCS was no longer significantly associated with SWS 
(may be due to lack of power in a smaller sample, as regression coefficient is similar), this 
procedure did not substantially change the results in the other models, indicating robustness of 
the observed associations (Supplement Table 2). 
3.4 Analyses of Indirect Effects 
 Mental distress (HSCL) partially and significantly explained variability in the 
relationship between the grouping variable and ISI and PSQI, respectively (Figure 1 and 2), 
whereas pain catastrophizing (PCS) was nonsignificant, and thus removed from the model. 
For insomnia (ISI) and global sleep quality (PSQI) as outcomes, the indirect pathways 
explained two thirds and half of the total effect, respectively. These findings suggest that the 
differences between the patient and the control sample with regard to self-reported insomnia 
and sleep quality is associated with levels of mental distress. Mental distress and pain 
catastrophizing did not significantly explain any other effects.  
 




The present cross-sectional case-control study reports substantial group differences 
between patients with chronic musculoskeletal pain (CMP) and healthy controls (HC) in self-
reported sleep disturbance. However, the group differences in sleep continuity (actigraphy) 
and sleep architecture (PSG), were minor. Moreover, mental distress was strongly associated 
with insomnia and reduced subjective sleep quality in both groups, as well as explained a 
proportion of the group (case-control) difference in these sleep measures. Mental distress was 
not related to the sleep efficiency (SE) or slow wave sleep (SWS), whereas pain 
catastrophizing was associated with less SWS in CMP solely. 
Our observations of large group differences in sleep quality and insomnia and less 
group differences in actigraphy or PSG measured sleep continuity align with previous studies 
of chronic pain conditions.13,19 We also found a smaller group difference in sleep architecture 
with less SWS in the pain group. As reviewed by Bjurstrom,3 controlled clinical studies 
including PSG are generally of small sample size, and there are somewhat diverging PSG 
findings regarding sleep architecture in patients with fibromyalgia and chronic widespread 
pain compared to healthy controls. Findings also diverged in two recent meta-analyses, one in 
patients with fibromyalgia and one in chronic pain associated with various conditions 
(however not including cancer and spinal cord injury), where only the former reported 
reduced SWS.13,15 Thus, the role of SWS in pain does not seem to be firmly established, and 
may be dependent on the pain condition. The group differences in objective sleep parameters 
are generally smaller, and one may question whether a group difference in SE of less than 
three percent and in SWS of approximately 15 minutes, as in this study, are of significant 
clinical importance.  
In the current study, mental distress statistically explained a substantial proportion of 
the variation in reported insomnia and sleep quality, as well as partially explained the CMP-
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HC difference in these self-report measures. The strong association between affective 
measures and self-report sleep measures in pain patients is well documented,1,11,26,28,29 and 
two previous studies of sickle cell disease and rheumatoid arthritis have reported negative 
mood/depression as a mediator of the relationship between pain intensity and sleep 
quality.26,28 We did not observe any associations between mental distress and actigraphy-
recorded SE, which also converges with previous studies.12,18,19 As an extension of previous 
studies, we included actigraphy and PSG sleep measures in the mediation analyses, which 
disconfirmed any role of mental distress as a mediator of SE or SWS. These findings indicate 
that self-reported sleep measures, but not actigraphy or PSG measures, overlap with affective 
dimensions. Potential reasons for this may include measurement modality (self-reported vs. 
clinician evaluated insomnia and depression), diagnostic overlap between depression and 
sleep disturbance as these phenomena share clinical features such as fatigue and insomnia, or 
that actigraphy and PSG measures may reflect some homeostatic or circadian dimensions 
undetected by self-report measures. Apparently, sleep measures obtained by different 
modalities seem to probe different aspects of sleep functioning and its relation to pain. Future 
studies should examine whether these differences are complementary or clinically 
qualitatively different.  
A cross-sectional design precludes any causal inferences from mediation modeling, as 
such models basically presume that the exposure occurs before the outcome and preferably 
also before the mediator. The proposed causal order tested in the present cross-sectional study 
is therefore tentative rather than conclusive. Although the grouping variable in our mediation 
analysis would not be meaningful to specify as a mediator or as an outcome, sleep quality and 
insomnia might instead be specified as a mediator of the pain-mental distress relationship. 
Indeed, previous mediation studies have reported mood and depressive symptoms as 
mediators of the sleep-pain relationship, as well as the reverse, i.e., pain-sleep relationship, as 
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our study represents.32 Additionally, studies have tested sleep as a mediator of the pain-
anxiety/depression relationship.49-51 and of the pain catastrophizing-pain persistence 
relationship.31 In one of these studies, PSG measured SE was a mediator of the pain-
anxiety/depression relationship,49 whereas the other studies solely applied self-reported sleep 
measures. Taken together, the findings of these mediation studies suggest that common 
neurobiological pathways may underpin symptoms of pain, depression and sleep 
disturbance.33 To permit causal inferences to be drawn about mediation and mechanism 
between pain and sleep more reliably, longitudinal studies that ensure the temporal ordering 
of the variables are needed.  
Polysomnography recordings allowed estimation of factors associated with changes in 
sleep architecture. The shift from SWS to more light sleep in this study was associated with 
the level of pain catastrophizing. This is a novel finding indicating a possible association 
between pain related cognitive processes and SWS in patients with chronic musculoskeletal 
pain. The Pain Catastrophizing Scale taps helplessness, magnification and rumination with 
negative pain-related thoughts and is associated with increased pain sensitivity and persistent 
pain.37,52 When combined with sleep disturbances it may also be associated with central 
sensitization and clinical pain, where the rumination component in particular seems to be 
involved.31,53  
In good sleepers, homeostatic factors will typically ensure compensatory increase in 
SWS following SWS deprivation, whereas in insomnia there is a lack of such compensation.54 
The models of psychophysiological hyperarousal and dysregulation of the sleep homeostasis 
have been proposed as potential mechanisms.54,55 Presleep cognitive arousal, including 
rumination, seems to be associated with reduced sleep quality, whereas mixed results are 
reported for associations with actigraphy measured SE in pain patients.12,19,30 Our findings of 
the association between pain catastrophizing and SWS may thus indicate that pain-specific 
Sleep disturbance in chronic musculoskeletal pain 
18 
 
cognitive arousal is involved in the loss of SWS in chronic pain patients. This may be a pain-
specific version of the hyperarousal of insomnia.  
In the current study we excluded participants with previously diagnosed sleep 
disordered breathing (SDB). Over recent years PSG scoring criteria with varying sensitivity to 
detect respiratory events have been recommended, resulting in large variations in AHI and 
prevalence estimates of sleep disordered breathing (SDB).56,57 Considering this source of 
variation in AHI, one may argue that the diagnosis of SDB in asymptomatic persons should 
not solely be based on the generally accepted cut-off score of AHI> 15.57,58 Due to these 
considerations we chose not to exclude participants on the basis of the apnea-hypopnea index 
(AHI) emerging from the PSG in the study, but rather controlled for AHI as a continuous 
variable in the statistical models. As removing participants with AHI> 15, as a sensitivity test 
of the regression analyses, did not substantially change our results this seems like a reasonable 
approach.  
In the current study, there was no group difference in AHI, yet sleep disordered 
breathing (SDB) has previously been proposed to be associated with pain.15,59 It remains to be 
established how SDB contributes to pain, but treatment of comorbid obstructive sleep apnea 
should always be considered, and it should be further studied if such treatment could possibly 
also have an effect on pain in patients with comorbid SDB and chronic pain.  
There are several limitations to this study. The cross-sectional design prevents any 
causal inference of associations between sleep, pain and mental distress. For such inferences 
one must rely on longitudinal studies. The sample size, with 109 subjects, was sufficient to 
detect clinically meaningful group differences, yet restricting the number of covariates to be 
included in the regression model. We chose to perform one night of PSG in order to prevent 
attrition, since most persons find the PSG equipment somewhat uncomfortable to wear. We 
may have introduced some first night effects,60 yet presumably proportionate in both groups 
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that were compared,15 and minimized by performing the PSG in the patients’ home 
environment. In this study patients and controls were instructed to go about their lives as 
usual. This increases the ecological validity of the results, but also adds some diversity of 
uncontrolled factors, such as sleep schedule, diet, and activity. Several relevant confounders 
could be controlled for in the regression models (age, gender, education, AHI). Yet, there are 
possible confounders, such as activation of stress responses, and possibly also chronotypes, 
that were not measured. These are factors that may be associated with both sleep problems, 
mental distress and pain, and may thus possibly explain some of the associations observed in 
this study.33,61 
Strengths of the study are the comprehensive recordings of sleep across multiple 
modalities, allowing assessment of various aspects of sleep. Since the association between 
sleep and pain may vary between pain conditions,6 the fairly homogenous sample of pain 
patients may be an advantage. Another advantage is the strictly blinded evaluation of 
actigraphy and PSG recordings.  
In conclusion, the study underlines the close relation between affective processes and 
sleep quality/insomnia, reflecting the commonly reported comorbidity of insomnia and 
depression, and where targeting both conditions simultaneously seem to yield superior 
treatment effects.62 Whereas mental distress in this study was related to sleep quality and 
insomnia, such relation was not found for measures of SE and SWS. On the other hand, pain 
catastrophizing, possibly reflecting pain related cognitive hyperarousal, was significantly 
associated with reduced SWS. Hence it is possible that interventions directed towards such 
cognitive processes may also affect sleep architecture, which remains a future perspective. 
The study illustrates the complementary properties of self-reported, actigraphic and 
polysomnographic sleep measurements. In a clinical setting, adding actigraphy and/or PSG to 
diagnose sleep disturbance, at least in selected patients, may add valuable information as these 
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modalities seem to reflect different aspects of sleep functioning, which may in turn be 
addressed in a multidisciplinary rehabilitation context. 
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Table 1. Distribution of ICD-10 diagnoses in pain 
sample 
 n 
M54.2 Cervicalgia 12 
M54.5 Low back pain 11 
M54.6 Pain in thoracic spine 1 
M54.8 Other dorsalgia 2 
M54.9 Dorsalgia, unspecified 11 
M79.1 Myalgia 10 
M79.6 Pain in limb 3 
M79.7 Fibromyalgia 6 
 
Table 2. Group Differences in Demographic Characteristics  
 Patients (n=56) Controls (n=53) p 
Age, M (SD) 41.7 (10.8) 41.8 (10.7) ns 
Female, n (%) 42 (75.0) 38 (71.7) ns 
Cohabitation, n (%) 35 (62.5) 40 (75.5) ns 
Higher education, n (%) 35 (62.5) 51 (96.2) < .001 
Employment, n (%) 42 (75.0) 52 (98.1) < .001 
Social benefit, n (%) 28 (50.0) 2 (3.8) < .001 
Good economy, n (%) 16 (28.6) 36 (67.9) < .001 
Medication    
Opioids, n (%) 6 (10.7) 0 .027 
Hypnotics, n (%) 3 (5.4) 0 ns 
Antidepressants, n (%) 6 (10.7) 0 .027 
Antiepileptic drugs, n (%) 3 (5.4) 0 ns 
NSAID, paracetamol, n (%) 18 (32.1) 0 <.001 
Other, n (%) 34 (60.7) 7 (13.2) <.001 
 Patients (n=53) Controls (n=53)  
BMI, M (SD) 27.0 (4.5) 25.4 (3.9) ns 
Note: BMI = body mass index, ns = p > .05 
 
 
Table 3. Group Differences in Self-report Questionnaire Measures 




CI 95% g 
BPI 4.12 (1.46) 0.81 (0.75) -3.76 to -2.87 2.81*** 
HSCL 1.73 (0.52) 1.24 (0.28) -0.64 to -0.33 1.16*** 
PCS 12.32 (10.69) 3.58 (3.44) -11.79 to -5.89 1.08*** 
Note:  *** p < .001, CI 95% = bootstrapped 95% confidence interval of mean difference, g = 
Hedge’s standardized mean difference, BPI = Brief Pain Inventory, HSCL = Hopkins 
Symptom Checklist, PCS = Pain Catastrophizing Scale  
 







CI 95% g 
Self-report instruments     
   ISI sum 11.9 (7.0) 4.1 (4.3) -9.93 to -5.66 1.32*** 
   PSQI global score 9.7 (4.3) 4.5 (2.4) -6.55 to -3.97 1.47*** 
Actigraphy     
   SOL, minutes 16.4 (18.1) 9.4 (8.0) -12.56 to -2.22 0.49* 
   WASO, minutes 36.1 (15.5) 29.0 (10.4) -12.22 to-2.20 0.53** 
   TST, minutes 398.7 (48.9) 399.8 (39.7) -15.47 to 17.65 -0.02 
   SE, % 86.7 (5.0) 89.5 (4.0) 1.09 to 4.45 -0.61** 
PSG Patients (n=53) Controls (n=51)   
   SOL, minutes 23.0 (32.0) 16.9 (18.3) -16.56 to 3.29 0.23 
   WASO, minutes 29.3 (30.6) 22.3 (18.6) -16.85 to 2.20 0.27 
   TST, minutes 395.8 (75.3) 384.6 (54.9) -36.22 to 14.61 0.17 
   SE, % 88.3 (9.5) 90.7 (5.9) -0.55 to 5.46 -0.30 
   N1, % of TST 10.8 (5.7) 10.5 (5.2) -2.36 to 1.88 0.05 
   N2, % of TST 47.0 (6.5) 43.5 (8.4) -6.47 to -0.62 0.46* 
   N3, % of TST 22.7 (7.9) 26.7 (10.6) 0.57 to 7.66 -0.43* 
   REM, % of TST 19.5 (5.4) 19.3 (4.8) -2.20 to 1.78 0.04 
N3 latency, minutes 53.9 (56.9) 41.8 (29.6) -30.79 to 3.83 0.26 
   Arousal index                             9.6 (6.8) 10.6 (6.3) -1.74 to 3.55 -0.15 
   Sleep stage change index 13.0 (3.9) 12.9 (3.2) -1.52 to 1.19 0.03 
   Wake bout index 1.83 (1.21) 1.74 (0.99) -0.50 to 0.33  
 Patients (n=49) Controls (n=50)   
   AHI 11.5 (11.9) 8.6 (8.5) -7.03 to 1.15 0.28 
   AHI > 15, n (%) 14 (28.6) 9 (18) ns  
 Patients (n=51) Controls (n=47)   
   PLMI 10.0 (11.8) 9.3 (16.9) -6.33 to 5.39 0.05 
Note: * p < .05, ** p < .01, *** p < 0.001, CI 95% = bootstrapped 95% confidence intervals of mean difference, g = Hedge’s standardized mean difference, 
ISI = Insomnia Severity Index, PSQI = Pittsburgh Sleep Quality Index, SOL = sleep onset latency, WASO= wake after sleep onset, TST = total sleep time, SE = 
sleep efficiency, AHI = apnea hypopnea index, PLMI= periodic limb movement index.  
Table 5. Mental Distress (HSCL) and Pain Catastrophizing (PCS) as predictors of sleep measures, separately in chronic musculoskeletal pain (CMP) and 
healthy control (HC) group 
Sleep outcome  CMP HC 
Predictor Adj R2 B (CI 95%) t Adj R2 B (CI 95%) t 
ISI  .62   .54   
HSCL  9.40 (6.30 to13.64) 5.02 ***  11.11 (6.46 to 15.69) 4.84 *** 
PCS  -.04 (-.24 to .14) -.39 ns  .10 (-.18 to .40) .65 ns 
Gender  -1.37 (-4.35 to 2.37) -.80 ns  .48 (-1.73 to 2.91) .40 ns 
Age  .07 (-.08 to .19) .93 ns  .08 (-.06 to .20) 1.18 ns 
Education  -.19 (-3.19 to 2.51) -.13 ns  4.75 (.83 to 8.08) 2.69 * 
AHI  .16 (-.00 to .30) 2.11 *  -.06 (-.22 to .23) -.55 ns 
PSQI  .37   .52   
HSCL  5.43 (2.64 to 8.29) 3.76 **  5.97 (3.24 to 9.29) 4.02 *** 
PCS  -.05 (-.19 to .13) -.56 ns  .15 (-.06 to .33) 1.49 ns 
Gender  -.60 (-3.15 to 2.19) -.44 ns  -54 (-.70 to 1.76) .87 ns 
Age  -.01 (-.15 to .11) -.22 ns  .04 (-.05 to .10) .92 ns 
Education  -.73 (-2.94 to 1.90) -.59 ns  2.28 (.69 to 4.21) 2.60 * 
AHI  .10 (-.04 to .20) 1.72 ns  -.05 (-14 to .13) -.69 ns 
SEactigraphy .05   .03   
HSCL  -2.74 (-7.21 to 1.93) -1.19 ns  -4.14 (-11.05 to 1.06) -1.33 ns 
PCS  .14 (-.06 to .34) 1.38 ns  -.22 (-.63 to .25) -.98 ns 
Gender  -2.31 (-6.64 to 1.61) -1.10 ns  .47 (-1.63 to 3.01) .39 ns 
Age  .15 (.03 to .28) 2.33 *  -.09 (-.24 to .05) -1.19 ns 
Education  1.04 (-2.51 to 4.62) .58 ns  -4.63 (-8.63 to -1.01) -2.51 * 
AHI  -.09 (-.26 to .07) -1.10 ns  .13 (-13 to .32) 1.17 ns 
SWS .04   .07   
HSCL  6.41 (-.08 to 12.88) 1.93 ns  -.11 (-9.15 to 14.11) -.02 ns 
PCS  -.37 (-.67 to -.05) -2.34 *  -.07 (-1.13 to .80) -.13 ns 
Gender  3.16 (-3.18 to 9.07) 1.00 ns  -3.81 (-9.51 to 3.28) -1.20 ns 
Age  -.03 (-.39 to .25) -.21 ns  -.50 (-.94 to -.15) -2.47 * 
Education  1.13 (-3.98 to 6.16) .44 ns  -.03 (-18.51 to 11.97) -.00 ns 
AHI  -.09 (-.35 to .29) -.53 ns  .31 (-.13 to .71) 1.53 ns 
Note: * p< .05, ** p< .01, ***p< .001, ISI: Insomnia Severity index, PSQI: Pittsburgh Sleep Quality index, SE: Sleep Efficiency, SWS: Slow Wave Sleep, HSCL: 





c=7.80 (CI 5.59 – 10.01)*** 
ab=5.04 








c’=2.62 (CI 1.43 -3.81)*** 
c=5.26 (CI 3.92-6.60)*** 
a*b=2.64 





Supplementary table 1. Bivariate Correlation. Healthy Controls Top Right, Chronic Musculoskeletal Pain Bottom Left 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1 BPI  .23 .37** .32* .29* .34* .01 -.27* -.24 .05 -.08 .06 -.05 .17 .31* .11 
2 PCS .53**  .36** .29* .40** .31* .02 .10 -.20 -.02 .01 -.00 -02 .09 .12 .14 
3 HSCL .42** .80**  .74** .71** .20 .10 -.03 -.22 .27 -.11 .06 -.24 .49** -.06 .19 
4 ISI .37** .62** .76**  .88** .25 -.01 -.04 -.10 .09 -.12 .10 -.11 .36* -.08 .14 
5 PSQI .37** .50** .63** .75**  .35** -.07 .04 -.09 .06 -.12 .10 -.09 .28 -.08 .06 
6 SOLactigraphy .19 .17 .13 .09 .17  .13 -.26 -.60** -.12 -.08 -.01 .29* -.04 -.11 .02 
7 WASOactigraphy .18 .12 .17 .08 .18 .09  .01 -.76** .35* .10 -.32* .15 -.06 -.09 .32* 
8 TSTactigraphy .16 .09 .07 .02 -.08 .10 -.18  .41** .10 -.09 .02 .02 -.12 -.08 -.06 
9 SEactigraphy -.17 -.09 -.12 -.05 -.18 -.62** -.69** .41**  -.13 -.08 .21 -.19 -.01 .07 -.26 
10 N1 .20 .06 -.09 .12 .04 .09 .17 -.10 -.18  -.07 -.41** -.07 .31* .11 .18 
11 N2 .13 .39** .35 .29 .25 .05 .15 .16 -.04 .08  -.76** .00 .02 .34* .07 
12 N3 -.26 -.23 -.06 -.21 -.09 -.10 -.09 -.04 .09 -.57** -.61**  -.42** -.09 -.26 -.19 
13 REM .02 -.20 -.23 -.16 -.21 -.01 -.24 -.03 .11 -.33* -.39 -.12  -.17 -.13 .10 
14 AHI .17 .23 .08 .35* .28 -.13 .11 -.38** -.12 .46** -.05 -.17 -.20  .27 .28 
15 PLMI -.08 -.13 -.14 -.06 -.01 -.12 -.11 -.40** -.04 .05 -.23 .26 -.16 .23  .03 
16 ARI .09 .10 .07 .17 .10 -.23 .16 -.22 -.07 .09 -.17 .08 -.01 .50** .19  
Note: * p<.05, ** p<.01, BPI: Brief Pain Inventory, PCS: Pain Catastrophizing Scale, HSCL: Hopkin Symptom Checklist, ISI: Insomnia Severity Index, PSQI: Pittsburgh 
Sleep Quality Index, SOL: Sleep Onset Latency, WASO: Wake after Sleep Onset, TST: Total Sleep Time, SE: Sleep Efficiency, N1/N2/N3/REM: Sleep Stages as 
Proportion of TST, AHI: Apnea Hypopnea Index, PLMI: Periodic Limb Movement Index, ARI: Arousal Index. Indexes Specified as Event/Hour 
 
Supplementary table 2 Mental Distress (HSCL) and Pain Catastrophizing (PCS) as predictors of self-report and objective sleep measures in pain and 
healthy control samples separately, excluded participants with AHI > 15. 
Sleep outcome 
Predictor    
CMP HC 
Adj R2 B (CI 95%) t Adj R2 B (CI 95%) t 
ISI  .57   .45   
HSCL  11.40 (6.10 to 17.90) 3.82 **  13.41 (6.49 to 18.49) 4.39 *** 
PCS  -.04 (-.33 to .19) -.31 ns  .10 (-.20 to .47) .59 ns 
Gender  -1.02 (-5.49 to 3.33) -.44 ns  -.21 (-2.57 to 2.19) -.17 ns 
Age  .03 (-.13 to .18) .36 ns  .04 (-.06 to .14) .82 ns 
Education  .33 (-3.11 to 3.81) .19 ns  5.24 (2.98 to 7.94) 4.16 ** 
PSQI  .31   .53   
HSCL  6.26 (2.28 to 10.25) 3.01 **  8.70 (4.95 to 11.32) 5.43*** 
PCS  -.09 (-.30 to .15) -.76 ns  .11 (-.10 to .31) 1.06 ns 
Gender  -.51 (-4.02 to 3.49) -.26 ns  .60 (-.55 to 1.81) .99 ns 
Age  .01 (-.12 to .13) .10 ns  .01 (-.04 to .07) .32 ns 
Education  .02 (-2.72 to 3.11) .01 ns  2.42 (1.12 to 3.68) 3.81 ** 
SEactigraphy .07      
HSCL  -.24 (-5.69 to 5.09) -.09 ns  -5.16 ( -14.29 to 3.95) -1.13 ns 
PCS  -.02 (-.31 to .25) -.14 ns  -.18 (-.68 to .29) .75 ns 
Gender  -1.53 (-8.38 to 3.80) -.49 ns  .79 (-1.68 to 3.54) .59 ns 
Age  .13 (-.01 to .28) 1.78 ns  -.08 (-.22 to .04) -1.23 ns 
Education  2.48 (-1.52 to 6.53) 1.24 ns  -5.01 (-8.18 to -1.80) -3.04 * 
SWS  -.07   .07   
HSCL  5.25 (-4.37 to 12.76) 1.22 ns  8.45 (-13.37 to 31 01) .77 ns 
PCS  -.35 (-.75 to .12) -1.57 ns  -.47 (-1.67 to .72)  -.79 ns 
Gender  2.40 (-6.48 to 10.12) .56 ns  -.90 (-9.27 to 6.82) -.22 ns 
Age  -.11 (-.48 to .27) -.56 ns  -.42 (-.83 to  - .03) -2.07 * 
Education  .03 (-6.46 to 6.37) .01 ns  10.00 (1.61 to 19.44) 2.24 ns 
Note: * p< .05, ** p< .01, ***p< .001, CMP: Chronic Musculoskeletal Pain, HC: Healthy Control, ISI: Insomnia Severity index, PSQI: Pittsburgh Sleep Quality 
index, SE: Sleep Efficiency, SWS: Slow Wave Sleep, HSCL: Hopkin Symptom Checklist, AHI: Apnea Hypopnea Index 
 
